BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2025; 16(12): 103683
Published online Dec 24, 2025. doi: 10.5306/wjco.v16.i12.103683
Stem cell collection from peripheral blood of multiple myeloma patients
Jonah Lee, Quincy Seigel, Spencer Lee, Emily Green, Sara Chitlik, Veronika Lobova, Paul Eastvold, Chris Gresens, Erin A Kaya
Jonah Lee, Spencer Lee, Department of Radiation Oncology, Cancer Care Northwest, Spokane, WA 99204, United States
Quincy Seigel, Department of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, TX 77555, United States
Emily Green, College of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States
Sara Chitlik, College of Medicine, Rush Medical College, Chicago, IL 60612, United States
Veronika Lobova, General Surgery, UCSF Fresno Surgery, Fresno, CA 93701, United States
Paul Eastvold, Chris Gresens, Blood Center, Vitalant Blood Centers, Spokane, WA 99201, United States
Erin A Kaya, Department of Radiation Oncology, Oregon Health Sciences University, Portland, OR 97239, United States
Author contributions: Lee J data collection, data analysis, interpretation of results, writing manuscript; Seigel Q writing manuscript, critical review of data and manuscript; Lee S data analysis, writing manuscript; Green E critical review of data and manuscript; Chitlik S critical review of data and manuscript; Lobova V critical review of data and manuscript; Eastvold P project administration; Gresens C critical review of data and manuscript; Kaya EA supervision, visualization, critical review of data and manuscript.
Institutional review board statement: IRB review/approval was not required for this retrospective analysis due to only retrospectively analyzes patients' laboratory results.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None of the authors have conflicts of interest to disclose.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Erin A Kaya, MD, Department of Radiation Oncology, Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, United States. erinkaya@berkeley.edu
Received: November 28, 2024
Revised: March 9, 2025
Accepted: November 14, 2025
Published online: December 24, 2025
Processing time: 391 Days and 13.3 Hours
Abstract
BACKGROUND

The purpose of this paper is to demonstrate a practical stem cell collection method that provides sufficient stem cells for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients despite low peripheral CD34 (pCD34) counts and to describe the benefits of this method for MM patients with limited resources.

AIM

To demonstrate a practical method for stem cell collection.

METHODS

Stem cell collection data on the last 300 patients at a community cancer center in Washington were reviewed. We report on the methods of collection, including medications used and timing, used by the blood blank as well as their outcomes. The three MM patients with initially very low pCD34 counts all successfully underwent stem cell collection in a single trip to the transplant center for their ASCT.

RESULTS

Three patients whose pre-collection pCD34 counts were the lowest and less than 2.5 cells/μL were identified. These patients had the commonality of having multiple barriers to transportation and likely would have been able to make only one trip for the stem cell collections.

CONCLUSION

Despite particularly low pre-collection peripheral blood CD34 counts, successful autologous stem cell collection in MM patients is feasible by routinely adding plerixafor to granulocyte-colony stimulating factor on day 4 of mobilization. There is limited analysis demonstrating that sufficient stem cells for one or more transplants can be collected using this method. This practical and novel approach may benefit the high number of MM patients who face limited resources, finances, long travel times, and social support. These results are highly relevant to physicians treating similar patients.

Keywords: Multiple myeloma; Stem cell collection; Plerixafor; Peripheral CD43 count; Autologous stem cell collection

Core Tip: We are demonstrating a practical stem cell collection method that provides sufficient stem cells for autologous stem cell transplantation in multiple myeloma patients despite low peripheral CD34 (pCD34) counts and to describe the benefits of this method for patients with limited resources. We present three patients whose pre-collection pCD34 counts were less than 2.5 cells/μL and all successfully underwent stem cell collection in a single trip to the transplant center. This approach may benefit the high number of patients who face limited resources, finances, travel abilities, and social support.